1 cacy endpoint was termination of
adjudicated PSVT within 5 hours after study drug administration.
2 NODE-301 accrued 156 positively
adjudicated PSVT events treated with etripamil (n=107) or placebo (n
3 After the first or second
bolus,
PSVT converted to sustained sinus rhythm for > or =5 min
4 o terminate atrioventricular nodal-
dependent PSVT.
5 ophysiologic procedure because of
documented PSVT and were found to have dual AV node physiology or i
6 l nasal spray for self-administration
during PSVT in a medically unsupervised setting.
7 Etripamil self-administration
during PSVT was safe and well tolerated.
8 en required for an accurate diagnosis
during PSVT.
9 cing maneuvers that are commonly used
during PSVT in the electrophysiology laboratory.
10 n 37 vs. 69 years, p = 0.0002), had a
faster PSVT heart rate (mean 186 vs. 155 beats/min, p = 0.0006)
11 The second bolus was administered only
if PSVT persisted for 1 minute after the first bolus.
12 ermination of electrophysiologically
induced PSVT.
13 a history of symptomatic PSVT and
inducible PSVT at the time of a clinically indicated electrophysio
14 story of PSVT at times do not have
inducible PSVT in the electrophysiology laboratory.
15 single AV node echo beats, but no
inducible PSVT despite the administration of isoproterenol and atr
16 e-entrant tachycardia, n = 8) with
inducible PSVT sustained for > or =1 min during an electrophysiolo
17 ascular disease were labeled as having "
lone PSVT."
18 ildbearing years in 58% of females with
lone PSVT versus 9% of females with other cardiovascular dise
19 ther cardiovascular disease, those with
lone PSVT were younger (mean 37 vs. 69 years, p = 0.0002), ha
20 r cardiovascular disease and those with
lone PSVT.
21 in patients with documented but
noinducible PSVT who have evidence of dual AV node pathways.
22 vely and rapidly converted 90% (28 of 31)
of PSVT patients to normal sinus rhythm with no significant
23 ases as of July 1, 1991 and all new cases
of PSVT diagnosed from that day until June 30, 1993.
24 The frequency of the episodes
of PSVT ranged from > or = 1/day to 1/month.
25 Patients with a documented history
of PSVT at times do not have inducible PSVT in the electrop
26 Current knowledge
of PSVT has been derived primarily from otherwise healthy p
27 mponent of acute and long-term management
of PSVT.
28 iologic heterogeneity in the pathogenesis
of PSVT and the need for more population-based research on
29 first-line therapy to prevent recurrence
of PSVT.
30 d APs that were also associated with risk
of PSVT, and thus likely atrioventricular reentrant tachyca
31 ness of long-term pharmacotherapy to
prevent PSVT.
32 most effective therapy to prevent
recurrent PSVT.
33 vised in patients with symptomatic
sustained PSVT.
34 dy, tecadenoson rapidly terminated
sustained PSVT by depressing AV nodal conduction without causing h
35 Patients with a history of
symptomatic PSVT and inducible PSVT at the time of a clinically indi
36 ith paroxysmal supraventricular
tachycardia (
PSVT) in the electrophysiology laboratory.
37 of paroxysmal supraventricular
tachycardia (
PSVT) in the general population.
38 of paroxysmal supraventricular
tachycardia (
PSVT) often requires medically supervised intervention.
39 of paroxysmal supraventricular
tachycardia (
PSVT) to sinus rhythm.
40 ble paroxysmal supraventricular
tachycardia (
PSVT) who have evidence of dual atrioventricular (AV) no
41 ced paroxysmal supraventricular
tachycardia (
PSVT) without the clinically significant side effects ca
42 as: paroxysmal supraventricular
tachycardia (
PSVT), atrial fibrillation (AF), ventricular tachycardia
43 Paroxysmal supraventricular
tachycardia (
PSVT), defined as tachyarrhythmias that originate from o
44 an etripamil treatment effect in
terminating PSVT.
45 hycardia-mediated cardiomyopathy (1%) due
to PSVT.
46 Untreated PSVT is associated with adverse outcomes including high
47 When PSVT symptoms developed, patients applied a cardiac moni
48 The 3 variants associated
with PSVT and the SCN10A variant associated with AF, supporti
49 Approximately 50% of patients
with PSVT are aged 45 to 64 years and 67.5% are female.
50 stic tools in a large group of patients
with PSVT.
51 d efficacy of etripamil in 104 patients
with PSVT.
52 re are two distinct subsets of patients
with PSVT: those with other cardiovascular disease and those
53 ,000 new cases/year and 570,000 persons
with PSVT in the United States.